Objective: Reported herein is a potential strategy for sustained smooth muscle cell (SMC) inhibition with a virulenceattenuated herpes simplex virus (HSV). Experiments were conducted in vitro to demonstrate selective SMC cytotoxicity and in vivo to demonstrate reduced neointimal hyperplasia (NIH) in a clinically relevant animal model. Methods: In vitro: Cultured human umbilical artery smooth muscle cells (UASMC) and venous endothelial cells (HUVEC) were exposed to varying multiplicities of infection (MOI) of a ␥ 1 34.5-deleted HSV-1 virus (R849). Cell survival was assessed at 48 and 72 hours with a colorimetric MTT viability assay. In vivo: New Zealand White rabbit external jugular veins (n ‫؍‬ 21) were exposed to R849 (2.5 ؋ 10 6 pfu/mL) or culture medium at 110 to 120 mm Hg for 10 minutes, then fashioned as vein patches on carotid arteries. Carotid arteries were ligated distally to decrease blood flow and stimulate a hyperplastic response (ultra-low shear stress model). After 2, 4, 12, and 24 weeks, patched segments were perfusion-fixed with glutaraldehyde and morphometrically examined for NIH formation. Results: In vitro: At 48 hours, R849 exhibited preferential cytotoxicity to UASMC compared with HUVEC, with 11% ؎ 10% of UASMCs and 49% ؎ 8% of HUVECs surviving after infection with MOI ‫؍‬ 25 (P < .05). Higher MOI resulted in poor survival of both cell lines. In vivo: Blood flow was similarly reduced in all animals both at surgery (0.9 ؎ 0.1 mL/min vs 1.6 ؎ 0.3 mL/min) and at harvest (2.7 ؎ 0.4 mL/min vs 2.5 ؎ 0.5 mL/min). R849-infected patches exhibited markedly less NIH than control patches did at 2 weeks (162 ؎ 14 m vs 49 ؎ 6 m; P < .05), 4 weeks (190 ؎ 27 m vs 67 ؎ 8 m; P < .05), and 12 weeks (233 ؎ 18 m vs 113 ؎ 2 m; P < .05). Conclusion: The virulence-attenuated HSV strain R849 demonstrates selective cytotoxicity for SMC and is capable of sustained inhibition of NIH in an experimental model of vein graft failure. (J Vasc Surg 2003;37:1294-300.)
Neointimal hyperplasia (NIH) is the pathologic proliferation of vascular smooth muscle cells (SMC) in response to intervention. 1 When severe, the process leads to formation of new encroaching lesions within the vessel lumen, reduction in blood flow, and, ultimately, therapeutic failure. Occurring in 30% of percutaneous coronary angioplasty procedures, 50% of peripheral and coronary vein grafts, and up to 80% of percutaneous procedures performed to treat complex infrainguinal lesions, 2,3 this process remains the major obstacle to consistent, long-term success in treatment of arterial occlusive disease. Because NIH is surprisingly recalcitrant to any form of pharmacologic therapy, 4 new methods have been proposed and are under intense investigation. Much of the focus has been on genetic therapy, broadly defined as any strategy using recombinant nucleic particles, ranging from the very simple (eg, oligonucleotides) to the complex (eg, adenoviral vectors). The purpose of these experiments was to investigate the relative cytotoxicity of antiproliferative neurovirulenceattenuated herpes simplex virus (HSV)-1 (R849) on cultured vascular endothelial cells and SMC and to test the hypothesis that R849 can prevent formation of ultra-low shear-induced NIH in a model of a failing vein graft.
METHODS
Vector preparation. The recombinant virus R3617 lacking 1 kb DNA in each copy of the ␥ 1 34.5 gene was generated by cotransfecting rabbit skin cells with intact R4002 DNA and DNA of plasmid pRB3616. In this plasmid the sequences containing most of the coding domain of ␥ 1 34.5 have been deleted. The thymidine kinase (TK)negative (tk Ϫ ) progeny of the transfection were plated on 143TK-negative cells overlaid with medium containing bromodeoxyuridine. This procedure selects tk Ϫ viruses, and since the tk gene is present in both copies of the ␥ 1 34.5 gene the selected progeny of the transfection can be expected to contain deletions in both copies. The selected tk Ϫ virus was designated as R3617. For assays of neurovirulence, the deletion in the native tk Ϫ gene of R3617, which traces its origin from HSV-1 (F)⌬305, had to be repaired. This was done by cotransfection of rabbit skin cells with intact R3617 DNA and BamHI Q fragment containing the tk gene. 5 The virus selected for tk ϩ phenotype in 143TKnegative cells was designated R3616. The bacterial ␤-galactosidase reporter cassette was then inserted at the ␥ 1 34.5 promotor site of R3616 yielding the R849 strain. 6 Cytotoxicity assay. Human umbilical vein endothelial cells (HUVEC; BioWhittaker/Clonetics, Walkersville, Md) and umbilical artery smooth muscle cells (UASMC; BioWhittaker/Clonetics) were suspended in complete medium EGM bullet kit and SMGM-2 bullet kit, respectively, and grown to 100% confluence in P75 flasks in a 37°C incubator with humidified 5% carbon dioxide (CO 2 ). For the passage of cells, all reagent pack contents (Hank's balanced salt solution [HBSS], trypsin/ethylenediaminetetraacetic acid [EDTA], Trypsin Neutralizing Solution, BioWhittaker) were thawed in a 37°C water bath, and the exhausted media were removed and discarded. Cells were washed with enough HBSS to cover them, trypsin/EDTA was added, and flasks were gently agitated under an inverted microscope. With loss of adherence of cells, trypsin was inactivated with an equal volume of TNS. The cells were centrifuged at 1200 rpm for 5 minutes, and the pellet was resuspended in complete medium EGM and singlequots of EGM or in complete medium SMGM-2 with singlequots of SMGM-2, respectively.
A modified colorimetric assay based on the selective ability of living cells to reduce the yellow salt MTT (3-[4,5dimethylthiozol-2-yl]-2,5 diphenyl tetrazolium bromide; Sigma-Aldrich, St Louis, Mo) to formazan was used to quantitate HUVEC and UASMC viability after viral exposure and rescue with Acyclovir (Abbott Laboratories, North Chicago, Ill). HUVEC and UASMC were suspended in media and plated onto gelatin-coated 96-well flat-bottom microtiter plates at a density of 5 ϫ 10 3 in a volume of 0.1 mL. Cells were allowed to incubate overnight and then were exposed to HSV R849 suspended in HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid) buffered saline solution (HBS) for 2 hours at 37°C with humidified 5% CO 2 in concentrations of 0, 1, 2.5, 5, 7.5, 10, 25, and 50 MOI. After exposure the viral-containing fluid was aspirated off, media were replaced, and cells were returned to the incubator. At 48 and 72 hours the supernatant was again aspirated, and MTT 5 mg/mL was added to each well of the zero plate for 4 hours at 37°C. After formation of the formazan crystals, the supernatant was aspirated with attention to not disturb the underlying cell layer. The formazan crystals were then dissolved in 0.1 mL dimethyl sulfoxide (DMSO; Sigma), absorbance was measured at 515 nm with a microplate spectrophotometer (SpectraMax 340 004, Molecular Devices Corporation, Sunnyvale, Calif) interfaced with a personal computer (Apple Macintosh, Cupertino, Calif), and relative cell survival was calculated. The experiment was repeated twice again.
To assess acyclovir rescue, HUVEC and UASMC were suspended in media and plated as described. Cells were allowed to incubate overnight and then were exposed to HSV R849 suspended in HBS for 2 hours at 37°C with humidified 5% CO 2 at a concentration of 25 MOI. The supernatant was aspirated, 0.1 mL of complete medium EGM or complete medium SMGM-2 containing 0, 0.25, 0.5, 1.0, 2.5, 5.0, or 10 g/mL of acyclovir was added to each well, and the cells were returned to the incubator. At 72 hours the supernatant was again aspirated and MTT 5 mg/mL was added to each well of the zero plate and incubated for 4 hours at 37°C. The supernatant was then aspirated with attention to not disturb the underlying cell layer. The formazan crystals were dissolved in 0.1 mL DMSO, and absorbance was measured as described. The experiment was repeated twice again.
Animal operations. Animals were cared for in accordance with the University of Chicago Institutional Animal Care and Use Committee. Male New Zealand White rabbits (3.5-4 kg) were anesthetized with intramuscular injection of ketamine hydrochloride (40 mg/kg) and xylazine (5 mg/kg) augmented with isoflurane (0%-3%) titrated for effect via endotracheal intubation. Antibiotic prophylaxis was provided with enrofloxacin 10 mg/kg intramuscularly daily for 2 days. Intra-arterial pressure was monitored through a 22-gauge cannula placed in the contralateral ear artery. Using sterile technique, the external jugular vein was exposed and doubly cannulated with 22-gauge olivetipped cannulas. One cannula was used for irrigation and infection, and the other was used for intraluminal pressure monitoring. The main channel was infected with either vehicle (n ϭ 10) or R849 2.5 ϫ 10 6 pfu/mL (n ϭ 8) for 10 minutes at 110 mm Hg.
After infection, the vein was irrigated with saline solution, excised, and bivalved. The ipsilateral common carotid artery (CCA) was then exposed through the same incision, and the animal was systemically anticoagulated with heparin 200 U/kg intravenously. The CCA was doubly clamped, and a 1.5 cm longitudinal arteriotomy performed proximal to the cranial thyroid artery branch. The arteriotomy was reconstructed with external jugular vein patch angioplasty with running 8-0 polypropylene suture (TE-145; Davis-Geck, Manatee, PR) under 4.3ϫ loupe magnification. To reduce flow, the CCA was ligated distal to the small cranial thyroid artery branch. Ultrasonic transit-time flow through the graft was measured (HT207; Transonics Systems, Ithaca, NY) and recorded with a digital data acquisition system (Lab Master DMA; Scientific Solutions, Solon, Ohio). External measurements were made with digital calipers. The incision was closed, and the animals were allowed to recover. Anticoagulation was not reversed.
Harvest and analysis. After 2, 4, 12, or 24 weeks postoperative, the animals were anesthetized again and the vein patches reexposed. Intra-arterial pressure and blood flow through the patch were again measured and recorded. The proximal CCA was cannulated with an olive-tipped cannula on a three-way stopcock attached to a syringe and manometer. The artery was ligated distal to the patch, and the section was perfusion-fixed with 1.25% glutaraldehyde at 100 mm Hg for 10 minutes, excised, and divided into three sections, starting 1 mm distal to the beginning of the patch and ending 1 mm proximal to its end point. A 0.5 mm section was prepared with standard gold coating, and the endothelium was visualized with scanning electron microscopy. Five-millimeter sections were cut from each of the portions of the patch and stained with eosin, hematoxylin-eosin, and Weigert-van Gieson stain.
Three sections of each specimen were used for histomorphometric analysis. Digital images were acquired with a microscope equipped with a 3.0 mega pixel digital camera (Olympus, Melville, NY). Thickness of the neointima was digitally measured (Adobe Photoshop 6.0, San Jose, Calif) at 10 points along the venous patch from lumen to internal elastic lamina. Mean thickness was calculated by taking the average of all measurements. Statistical analysis was performed using SPSS 8.0 software (SPSS, Chicago, Ill). Comparison of differences in variance in the MTT assay was assessed with analysis of variance. Comparison of thickness was achieved with the Mann-Whitney U test for nonparametric variables. Significance was assigned at P Ͻ .05.
RESULTS
In vitro results. HUVEC infected with R849 at MOI of 1 had a relative cell survival of 86% Ϯ 8% at 48 hours and 81% Ϯ 4% at 72 hours. UASMC infected with R849 at MOI of 1 had a relative cell survival of 92% Ϯ 10% at 48 hours and 73% Ϯ 6% at 72 hours. As expected, a decreasing proportion of cells survived with increasing viral concentrations, with only 49% Ϯ 8% of HUVEC and 11% Ϯ 10% of UASMC surviving 48 hours after infection with MOI of 25 (P Ͻ .001 when compared with MOI ϭ 0). No cells survived to 72 hours at this viral concentration. UASMC showed significantly worse survival after infection with R849 than HUVEC did at 48 hours over a wide range of MOI (Fig 1) .
HUVEC infected with 25 MOI of R849 and rescued with 0.25 g/mL and 0.5 g/mL of acyclovir had a relative cell survival at 72 hours of 45% Ϯ 5% (P Ͻ .01) and 85% Ϯ 9% (P Ͻ .01), respectively, compared with 0% survival without acyclovir. UASMC infected with 25 MOI of R849 could not be rescued even with 10 g/mL of acyclovir (Fig 2) .
In vivo results. All animal operations were completed without complication, and 21 of 22 vein patches remained patent at harvest. There was no significant difference in mean blood flow in vehicle-treated versus viral-treated patches at implantation or harvest (Table) . However, the amount of NIH was significantly reduced in the R849treated groups after 2, 4, and 12 weeks (P Ͻ .05; Fig 1) . The reduction in NIH translated into an enhanced flow lumen, as evidenced by increased lumen radius in R849treated patches after 4 weeks. Decreased NIH and enhanced flow lumen in R849-treated patches seemed to be sustained after 24 weeks as well (Fig 3) , although the small number of animals (n ϭ 2 in each group) precluded statistical comparison. 
DISCUSSION
HSV-1 is a lytic, nonintegrating DNA virus that has demonstrated neurotropism and establishment of longterm infections. 7 Like adenovirus, HSV-1 can be manufactured in high titer, and it contains multiple nonessential genes that can potentially be deleted to reduce virulence or house transgenes. This had led some investigators to predict that HSV may become a major genetic agent for treatment of systemic disease. [8] [9] [10] However, the lytic and highly infectious nature of HSV and the lifelong potential for latency necessitate significant genetic engineering before therapeutic use.
HSV-1 has been extensively studied as therapy for malignant tumors of the central nervous system with a variety of genetic manipulations. 7, [11] [12] [13] [14] Its use in vascular tissue is limited, although there are a few reports of successful use of vascular SMCs, 15 skeletal muscle cells, [16] [17] [18] and cardiac myocytes. 19 It was first proposed to use viruses that lack TK, ribonucleotide reductase, or glycoprotein H coding regions, which reduced viral growth in nondividing cells. 15, [20] [21] [22] A second strategy, and the one proposed herein, centers on deletion of both copies of the ␥ 1 34.5 gene. 5, 23 The products of the ␥ 1 34.5 gene allow replication in the central nervous system, and phosphorylation of the ␣ subunit of the translation initiation factor eiF-2 involved in viral protein synthesis. Deletion of both copies of this gene potentially decreases virulence but still allows replication in dividing cells and possibly in stable episomal infection. Furthermore, the ␥ 1 34.5-deleted strain retains TK activity and thus is potentially controllable with exogenous acyclovir.
The herpes family of viruses may be the ideal agents for antiproliferative vascular gene therapy. They are highly penetrant in vascular tissue, 15 capable of generating prolonged infection in immunocompetent hosts, 10,24 strong inhibitors of the mammalian cell cycle, 23, 25 controllable with well-tolerated exogenous antiviral agents. 26 In a particularly noteworthy study by Miyatake et al 15 a conditionally replication-competent HSV strain (hrR3) effectively inhibited SMC proliferation in culture and in a rat model of arterial restenosis. In human beings, replication-competent HSV has been used as experimental treatment of malignant glioma. 7, 14, 27 The agent is welltolerated, and preliminary data are encouraging.
The hypothesis under study in this experiment was that a highly attenuated HSV mutant, R849, would be efficacious in preventing experimental pathologic vascular proliferation. Exposure of cultured vascular cells to R849 at MOI of 10 resulted in significant cytotoxicity, which was even more pronounced at higher viral concentrations and was completely reversible with acyclovir. R849 seems to have a predilection for SMCs over endothelial cells, a useful biologic property, given the need to preserve the antithrombotic endothelial cell layer while maximizing SMC inhibition. Indeed, R849 failed to induce thrombosis in this animal model even while mean blood flow was reduced to less than 6 mL/min for as long as 24 weeks.
R849 treatment significantly inhibited formation of NIH in this study. NIH was reduced by 50% to 70%, depending on the time point tested, and the effect was sustained over 6 months. In control animals, the chronically reduced shear stress appeared to slowly cause thickening and contraction of the vein patch reconstruction. In contrast, prevention of the thickening response with pretreatment with R849 rendered the patches thinner and larger, altering the chronic response to low shear. This was achieved with viral concentrations of only 10 6 pfu/mL, about 10 4 less than concentrations used in traditional adenoviral strategies. [28] [29] [30] [31] [32] [33] The actual amount and duration of infection was not specifically quantified in this study, although a previous report documented significant infection persisting up to 4 weeks, 6 and others have reported persistence for as long as 1 year. 10 In summary, the virulence-attenuated HSV strain R849 demonstrates differential cytotoxicity for SMC and is capable of sustained inhibition of NIH in an experimental model of vein graft failure. Attenuated HSV may be a viable agent for prevention or treatment of vascular proliferative disorders.
